Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOSEIT: Liraglutide in Knee Osteoarthritis
NCT02905864Phase 4Completed
- Start
- Nov 2016
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Liraglutide 3 mg with Placebo (2 arms). Primary endpoints: Change in body weight at 52 weeks and Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale at 52 weeks. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02905864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905864.